Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Latest News
thumbnail
Upstream & Downstream ProcessingBioprocessing Q3: After 18 challenging months, is the worst behind?
Bioprocessing Q3: After 18 challenging months, is the worst behind?
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.
Deal-Making
Pluri, BIRAD bring tumor-fighting MAIT cells to commercial viabilityPluri, BIRAD bring tumor-fighting MAIT cells to commercial viability
Pluri has collaborated with Bar-Ilan University to develop placental mucosal associated invariant (MAIT) T-cells for solid tumors. We spoke to the company’s spokesperson to find out more.
Regulations
Letter urges FTC to block Novo’s $16.5bn Catalent purchaseLetter urges FTC to block Novo’s $16.5bn Catalent purchase
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Facilities & Capacity
Q&A: Vetter SVP says sustainability is essential for long-term successQ&A: Vetter SVP says sustainability is essential for long-term success
As clients and employees demand industrywide environmental and social sustainability, companies must learn to integrate it into their daily operations.
Facilities & Capacity
MilliporeSigma bolsters oncology portfolio with $76m US expansionMilliporeSigma bolsters oncology portfolio with $76m US expansion
The company has tripled manufacturing capacity of antibody drug conjugates (ADCs) at its facility in St. Louis, Missouri.
Global Markets
Celltechna opens $54m gene therapy center in LithuaniaCelltechna opens $54m gene therapy center in Lithuania
The 8,000 square-meter facility is the first of the $7.6 billion Bio City project announced by Northway Healthcare Group.
Upstream & Downstream Processing
Bioprocessing Q3: After 18 challenging months, is the worst behind?Bioprocessing Q3: After 18 challenging months, is the worst behind?
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.
Regulations
Surviving BIOSECURE: US companies must prepare to avoid disruptionSurviving BIOSECURE: US companies must prepare to avoid disruption
“We need to take these concerns about the supply chain seriously and recognize that there’s immense capability in the US already,” says CRO Southern Research.
Regulations
Letter urges FTC to block Novo’s $16.5bn Catalent purchaseLetter urges FTC to block Novo’s $16.5bn Catalent purchase
Consumer advocacy groups, healthcare unions, and a US senator are all asking for government intervention.
Therapeutic Class
Governor unveils plans for $450m CGT innovation hub in New YorkGovernor unveils plans for $450m CGT innovation hub in New York
The state will invest $150 million in Long Island’s New York BioGenesis Park (NYBGP).
Therapeutic Class
Investors prioritize efficacy in the CGT biz, experts sayInvestors prioritize efficacy in the CGT biz, experts say
Drawing a roadmap on cell and gene therapy (CGT) markets, a panel of experts shed light on how investor behaviors and reimbursement practices are changing.
Upstream & Downstream Processing
MilliporeSigma bolsters oncology portfolio with $76m US expansionMilliporeSigma bolsters oncology portfolio with $76m US expansion
The company has tripled manufacturing capacity of antibody drug conjugates (ADCs) at its facility in St. Louis, Missouri.
Upstream & Downstream Processing
Bioprocessing Q3: After 18 challenging months, is the worst behind?Bioprocessing Q3: After 18 challenging months, is the worst behind?
Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.